{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:03:12Z","timestamp":1784167392885,"version":"3.55.0"},"reference-count":32,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: In patients with non-small cell lung cancer (NSCLC) treated with neoadjuvant chemo-immunotherapy, pulmonary resection can be technically demanding because of hilar\/mediastinal inflammation and fibrosis, potentially limiting the use of minimally invasive surgery (MIS). We report our single-center experience with MIS anatomical lung resections after neoadjuvant chemo-immunotherapy. Methods: We retrospectively collected consecutive NSCLC patients who underwent neoadjuvant chemo-immunotherapy followed by anatomical lung resection with an intended MIS approach at our institution between May 2018 and October 2025. Primary endpoints were feasibility and safety (conversion rate, intraoperative and postoperative complications, need for reoperation, and 30-day mortality). Results: Fifty-two patients were included. Mean age was 65.9 \u00b1 8.6 years; 27 (51.9%) were male. Median Charlson Comorbidity Index was 3 (IQR 2\u20134). Most patients had clinical stage III disease (IIIA 40.4%, IIIB 30.8%). Conversion to open surgery occurred in 7 cases (13.5%). One intraoperative complication was recorded (1.9%). Anatomical resections were predominantly lobectomies (including combined\/extended lobectomies) (88.4%); sleeve resections accounted for 11.5%, and bilobectomy for 7.7%. Postoperative complications occurred in 13 patients (25.0%); reoperation for complications was required in 1 case (1.9%). No deaths were recorded in the dataset. Pathological response showed pCR in 22 patients (42.3%) and MPR in 10 (19.2%). Conclusions: In our experience, minimally invasive anatomical lung resection after neoadjuvant chemo-immunotherapy for NSCLC is feasible, with an acceptable conversion rate and manageable morbidity, and is associated with a substantial rate of pathological response. Careful patient selection and surgical expertise remain essential.<\/jats:p>","DOI":"10.3390\/cancers18142244","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:55:21Z","timestamp":1783990521000},"page":"2244","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of Minimally Invasive Surgery After Chemo-Immunotherapy in Locally Advanced and Oligometastatic NSCLC: Technical Aspects and Surgical Outcomes"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-6168","authenticated-orcid":false,"given":"Giorgio","family":"Cannone","sequence":"first","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4687-2369","authenticated-orcid":false,"given":"Luigi","family":"Lione","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Sambataro","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-0597","authenticated-orcid":false,"given":"Alessandro","family":"Bonis","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7239-1248","authenticated-orcid":false,"given":"Vincenzo","family":"Verzeletti","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6493-7413","authenticated-orcid":false,"given":"Alessandro","family":"Rebusso","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Maria","family":"Comacchio","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Faccioli","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-4970","authenticated-orcid":false,"given":"Laura","family":"Bonanno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Sciences and Public Health\u2014DCTV, University of Padova Medical School, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Nicotra","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, S. Orsola-Malpighi Hospital, Via Massarenti 9, Pavillion 23rd, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schiavon","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dell\u2019Amore","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.2005.10.462","article-title":"Epidemiology of Lung Cancer: Looking to the Future","volume":"23","author":"Alberg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdq207","article-title":"Early Stage and Locally Advanced (Non-Metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"21","author":"Weder","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jtho.2024.02.011","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer","volume":"19","author":"Nishimura","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00184308","article-title":"ERS\/ESTS Clinical Guidelines on Fitness for Radical Therapy in Lung Cancer Patients (Surgery and Chemo-Radiotherapy)","volume":"34","author":"Brunelli","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.athoracsur.2018.02.030","article-title":"Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors","volume":"106","author":"Bott","year":"2018","journal-title":"Ann. Thorac. Surg."},{"key":"ref_8","first-page":"347","article-title":"Safety and Feasibility of Minimally Invasive Lobectomy after Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer","volume":"166","author":"McCarthy","year":"2022","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtcvs.2018.11.124","article-title":"Initial Results of Pulmonary Resection after Neoadjuvant Nivolumab in Patients with Resectable Non-Small Cell Lung Cancer","volume":"158","author":"Bott","year":"2019","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jtcvs.2023.09.073","article-title":"Surgical Outcomes after Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer","volume":"167","author":"Feldman","year":"2023","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101623","DOI":"10.1016\/j.xjon.2026.101623","article-title":"Feasibility and Oncologic Outcomes of Minimally Invasive Surgery after Induction Chemoimmunotherapy for Non-Small Cell Lung Cancer","volume":"30","author":"Comacchio","year":"2026","journal-title":"JTCVS Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/ejcts\/ezu028","article-title":"Revised ESTS Guidelines for Preoperative Mediastinal Lymph Node Staging for Non-Small-Cell Lung Cancer","volume":"45","author":"Dooms","year":"2014","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small-Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-380890-5.00002-8","article-title":"Genetic Basis for Susceptibility to Lung Cancer: Recent Progress and Future Directions","volume":"109","author":"Yokota","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bardhan, K., Anagnostou, T., and Boussiotis, V.A. (2016). The PD1:PD-L1\/2 Pathway from Discovery to Clinical Implementation. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00550"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Verma, S., Breadner, D., Mittal, A., Palma, D.A., Nayak, R., Raphael, J., and Vincent, M. (2024). An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. Cancers, 16.","DOI":"10.3390\/cancers16071302"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant Atezolizumab for Resectable Non-Small Cell Lung Cancer: An Open-Label, Single-Arm Phase II Trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab Compared with Neoadjuvant Chemotherapy Alone in Patients with Early-Stage Non-Small-Cell Lung Cancer (KEYNOTE-671): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1056\/NEJMe2403723","article-title":"Neoadjuvant or Perioperative Approach in Lung Cancer","volume":"390","author":"Garassino","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bardoni, C., Chiari, M., Bertolaccini, L., Diotti, C., De Fabiani, A., Nicolosi, G., Mazzella, A., Casiraghi, M., and Spaggiari, L. (2025). Surgical Outcomes After Neoadjuvant Chemo-Immunotherapy for Stage III NSCLC: A Systematic Review and Meta-Analysis. Cancers, 17.","DOI":"10.3390\/cancers17091426"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Trabalza Marinucci, B., Mancini, M., Siciliani, A., Messa, F., Piccioni, G., D\u2019Andrilli, A., Maurizi, G., Ciccone, A.M., Menna, C., and Vanni, C. (2025). Surgical Techniques for Non-Small-Cell Lung Cancer After Neoadjuvant Chemo-Immunotherapy: State of Art and Review of the Literature. Cancers, 17.","DOI":"10.3390\/cancers17040638"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhang, B., Xiao, Q., Xiao, H., Wu, J., Yang, D., Tang, J., Li, X., Wu, Z., Zhou, Y., and Wang, W. (2022). Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.858189"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11701-026-03326-4","article-title":"Multicenter Study Comparing Outcomes of Robotic Versus Video-Assisted Thoracoscopic Resection of Non-Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy","volume":"20","author":"Srivatsa","year":"2026","journal-title":"J. Robot. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/jso.27920","article-title":"Safety and Efficacy of Salvage Surgery after Treatment with Immune-Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Multicentric Study","volume":"131","author":"Schiavon","year":"2025","journal-title":"J. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2244\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:11:04Z","timestamp":1784164264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":32,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142244"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142244","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}